India’s Pricing Authority Has New Chief, Again
Executive Summary
India’s National Pharmaceutical Pricing Authority has a new chief, and pharma hopes that pricing policy outlook on the domestic market remains stable against the backdrop of a challenging operating environment globally.
You may also be interested in...
Has India’s Drug Pricing Authority Been Rendered Toothless?
India has put in place a new panel to act as a 'recommending body' to the National Pharmaceutical Pricing Authority, raising questions about the pricing body’s autonomy and whether its role has been 'usurped'. The pharma industry claims a balanced pricing regime may emerge under the new system but doesn’t rule out inter-department conflicts in the government.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet